U.S. Medical Eligibility Criteria for Contraceptive Use, 2024
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
The 2024 U.S. Medical Eligibility Criteria for Contraceptive Use (U.S. MEC) comprises recommendations for the use of specific contraceptive methods by persons who have certain characteristics or medical conditions.These recommendations for health care providers were updated by CDC after review of the scientific evidence and a meeting with national experts in Atlanta, Georgia, during January 25-27, 2023.The information in this report replaces the 2016 U.S. MEC (CDC.U.S. Medical Eligibility Criteria for Contraceptive Use, 2016.MMWR 2016:65[No.RR-3]:1-103).Notable updates include 1) the addition of recommendations for persons with chronic kidney disease; 2) revisions to the recommendations for persons with certain characteristics or medical conditions (i.e., breastfeeding, postpartum, postabortion, obesity, surgery, deep venous thrombosis or pulmonary embolism with or without anticoagulant therapy, thrombophilia, superficial venous thrombosis, valvular heart disease, peripartum cardiomyopathy, systemic lupus erythematosus, high risk for HIV infection, cirrhosis, liver tumor, sickle cell disease, solid organ transplantation, and drug interactions with antiretrovirals used for prevention or treatment of HIV infection); and 3) inclusion of new contraceptive methods, including new doses or formulations of combined oral contraceptives, contraceptive patches, vaginal rings, progestin-only pills, levonorgestrel intrauterine devices, and vaginal pH modulator.The recommendations in this report are intended to serve as a source of evidence-based clinical practice guidance for health care providers.The goals of these recommendations are to remove unnecessary medical barriers to accessing and using contraception and to support the provision of person-centered contraceptive counseling and services in a noncoercive manner.Health care providers should always consider the individual clinical circumstances of each person seeking contraceptive services.This report is not intended to be a substitute for professional medical advice for individual patients; when needed, patients should seek advice from their health care providers about contraceptive use. USDepartment of Health and Human Services | Centers for Disease Control and Prevention | MMWR | August 8, 2024 | Vol.73 | No. 4through a shared decision-making process with health care providers (10-14).Because of the history of and ongoing forced sterilization and reproductive coercion in the United States among persons of racial and ethnic minority groups, persons with disabilities, and other groups that have been marginalized, it is important that persons can select the method that best meets their needs to promote reproductive autonomy (10)(11)(12).This report replaces the 2016 version of U.S. MEC (6) with new and revised recommendations, on the basis of new evidence and input from experts.This updated document uses gender-inclusive language throughout.However, when summarizing published evidence that describes study populations by specific genders, the wording of the primary studies has been maintained for accuracy.A summary of new and revised recommendations from the 2016 U.S. MEC is provided (Appendix A).Notable updates include • addition of recommendations for persons with chronic kidney disease, specifically those with nephrotic syndrome, those receiving hemodialysis, and those receiving peritoneal dialysis; • revisions to recommendations for persons with certain characteristics or medical conditions (i.e., breastfeeding, postpartum, postabortion, obesity, surgery, history of deep venous thrombosis or pulmonary embolism with or without anticoagulant therapy, thrombophilia, superficial venous thrombosis, valvular heart disease, peripartum cardiomyopathy, systemic lupus erythematosus, cirrhosis, liver tumor, sickle cell disease, and solid organ transplantation); • revisions to recommendations for persons at high risk for HIV infection (this recommendation was developed and published in 2020) (15); • revisions to recommendations for drug interactions with antiretrovirals to include prevention in addition to treatment for HIV infection (this recommendation was developed and published in 2020) (15); and • inclusion of additional contraceptive methods, including new doses or formulations of combined oral contraceptives (COCs), contraceptive patches, vaginal rings, progestinonly pills (POPs), levonorgestrel intrauterine devices (LNG-IUDs), and vaginal pH modulator.U.S. MEC recommendations are meant to serve as a source of evidence-based clinical guidance for health care providers and can support the provision of person-centered contraceptive counseling and services in a noncoercive manner.Health care providers should always consider the individual clinical circumstances of each person seeking contraceptive services.This report is not intended to be a substitute for professional medical advice for individual patients; when needed, patients should seek advice from their health car
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The PRISMA 2020 statement: An updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · BMJ · doi:10.1136/bmj.n71 · Cited by 108,283
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
Guyatt, G. H., Oxman, A. D., Vist, G. E., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39489.470347.ad · Cited by 23,305
GRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tables
Guyatt, G., Oxman, A. D., Akl, E. A., Kunz, R., Vist, G., Brozek, J., Norris, S., Falck-Ytter, Y., Glasziou, P., & deBeer, H. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.04.026 · Cited by 10,681
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J., Bossuyt, P., Boutron, I., Hoffmann, T., mulrow, C., Shamseer, L., Tetzlaff, J., Akl, E., Brennan, S. E., et al. (2020) · doi:10.31222/osf.io/v7gm2_v1 · Cited by 8,090
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J., Bossuyt, P., Boutron, I., Hoffmann, T., mulrow, C., Shamseer, L., Tetzlaff, J., Akl, E., Brennan, S. E., et al. (2020) · doi:10.31222/osf.io/v7gm2 · Cited by 5,177
Sexually Transmitted Infections Treatment Guidelines, 2021
Workowski, K. A., Bachmann, L. H., Chan, P. A., Johnston, C. M., Muzny, C. A., Park, I., Reno, H., Zenilman, J. M., & Bolan, G. A. (2021) · MMWR. Recommendations and Reports · doi:10.15585/mmwr.rr7004a1 · Cited by 3,018
Cerebrovascular accidents in sickle cell disease: rates and risk factors.
(1998) · PubMed · doi:10.1182/blood.v91.1.288 · Cited by 1,694
U.S. Medical Eligibility Criteria for Contraceptive Use, 2016
Curtis, K. M., Tepper, N. K., Jatlaoui, T. C., Berry-Bibee, E., Horton, L. G., Zapata, L. B., Simmons, K. B., Pagano, H. P., Jamieson, D. J., & Whiteman, M. K. (2016) · MMWR. Recommendations and Reports · doi:10.15585/mmwr.rr6503a1 · Cited by 1,456
Self-citationWorld Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contarception (1995) · The Lancet · doi:10.1016/s0140-6736(95)91926-0 · Cited by 631
Oral Contraceptives and the Risk of Myocardial Infarction
Tanis, B. C., van den Bosch, M. A. A. J., Kemmeren, J. M., Cats, V. M., Helmerhorst, F. M., Algra, A., van der Graaf, Y., & Rosendaal, F. R. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa003216 · Cited by 367
Petta, C. A., Ferriani, R. A., Abrao, M. S., Hassan, D., Rosa e Silva, J. C., Podgaec, S., & Bahamondes, L. (2005) · Human Reproduction · doi:10.1093/humrep/deh869 · Cited by 363
Ahmed, K., Baeten, J. M., Beksinska, M., Bekker, L.-G., Bukusi, E. A., Donnell, D., Gichangi, P. B., Heller, K. B., Hofmeyr, G. J., Justman, J., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31288-7 · Cited by 299
Use of a levonorgestrel-releasing intrauterine device in the treatment of rectovaginal endometriosis
Fedele, L., Bianchi, S., Zanconato, G., Portuese, A., & Raffaelli, R. (2001) · Fertility and Sterility · doi:10.1016/s0015-0282(00)01759-3 · Cited by 290
Wahl, D., Guillemin, F., de Maistre, E., Perret, C., Lecompte, T., & Thibaut, G. (1997) · Lupus · doi:10.1177/096120339700600510 · Cited by 285
Vercellini, P., Frontino, G., De Giorgi, O., Aimi, G., Zaina, B., & Crosignani, P. G. (2003) · Fertility and Sterility · doi:10.1016/s0015-0282(03)00608-3 · Cited by 263
Cromer, B. A., Blair, J. M., Mahan, J. D., Zibners, L., & Naumovski, Z. (1996) · The Journal of Pediatrics · doi:10.1016/s0022-3476(96)70148-8 · Cited by 241
Scholes, D., LaCroix, A. Z., Ichikawa, L. E., Barlow, W. E., & Ott, S. M. (2005) · Archives of Pediatrics & Adolescent Medicine · doi:10.1001/archpedi.159.2.139 · Cited by 221
Lamotrigine plasma levels reduced by oral contraceptives
Sabers, A., Buchholt, J. M., Uldall, P., & Hansen, E. L. (2001) · Epilepsy Research · doi:10.1016/s0920-1211(01)00305-9 · Cited by 219
Martinelli, I., Lensing, A. W. A., Middeldorp, S., Levi, M., Beyer-Westendorf, J., van Bellen, B., Bounameaux, H., Brighton, T. A., Cohen, A. T., Trajanovic, M., et al. (2016) · Blood · doi:10.1182/blood-2015-08-665927 · Cited by 219
Oral contraceptives for pain associated with endometriosis
Brown, J., Crawford, T. J., Datta, S., & Prentice, A. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001019.pub3 · Cited by 199
Injectable Hormone Contraception and Bone Density: Results from a Prospective Study
Scholes, D., LaCroix, A. Z., Ichikawa, L. E., Barlow, W. E., & Ott, S. M. (2002) · Epidemiology · doi:10.1097/00001648-200209000-00015 · Cited by 187
Kjos, S. L. (1998) · JAMA · doi:10.1001/jama.280.6.533 · Cited by 174
Beerthuizen, R., van Beek, A., Massai, R., Mäkäräinen, L., Hout, J. I., & Bennink, H. C. (2000) · Human Reproduction · doi:10.1093/humrep/15.1.118 · Cited by 127
Kaunitz, A. M., Darney, P. D., Ross, D., Wolter, K. D., & Speroff, L. (2009) · Contraception · doi:10.1016/j.contraception.2009.02.005 · Cited by 123
Bone mineral density in adolescent females using depot medroxyprogesterone acetate
Lara-Torre, E., Edwards, C. P., Perlman, S., & Hertweck, S. P. (2004) · Journal of Pediatric and Adolescent Gynecology · doi:10.1016/j.jpag.2003.11.017 · Cited by 117
Use of Depot Medroxyprogesterone Acetate and Fracture Risk
Meier, C., Brauchli, Y. B., Jick, S. S., Kraenzlin, M. E., & Meier, C. R. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0032 · Cited by 90
SKOUBY, S. O., ANDERSEN, O., SAURBREY, N., & KÜHL, C. (1987) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-64-3-519 · Cited by 83
WONG, A. Y. K., TANG, L. C. H., & CHIN, R. K. H. (2010) · Australian and New Zealand Journal of Obstetrics and Gynaecology · doi:10.1111/j.1479-828x.2010.01152.x · Cited by 82
Xu, Z., Li, Y., Tang, S., Huang, X., & Chen, T. (2015) · Thrombosis Research · doi:10.1016/j.thromres.2015.04.021 · Cited by 80
Use of Depot Medroxyprogesterone Acetate Contraception and Incidence of Bone Fracture
Lanza, L. L., McQuay, L. J., Rothman, K. J., Bone, H. G., Kaunitz, A. M., Harel, Z., Ataher, Q., Ross, D., Arena, P. L., & Wolter, K. D. (2013) · Obstetrics & Gynecology · doi:10.1097/aog.0b013e318283d1a1 · Cited by 78
Horton, L. G., Simmons, K. B., & Curtis, K. M. (2016) · Contraception · doi:10.1016/j.contraception.2016.05.014 · Cited by 75
Self-citationEffect of a levonorgestrel intrauterine system on women with type 1 diabetes: a randomized trial
Rogovskaya, S., Rivera, R., Grimes, D. A., Chen, P.-L., Pierre-Louis, B., Prilepskaya, V., & Kulakov, V. (2005) · Obstetrics & Gynecology · doi:10.1097/01.aog.0000156301.11939.56 · Cited by 75
Anastasilakis, A. D., Tsourdi, E., Makras, P., Polyzos, S. A., Meier, C., McCloskey, E. V., Pepe, J., & Zillikens, M. C. (2019) · Bone · doi:10.1016/j.bone.2019.07.006 · Cited by 71
Skouby, S. O., Kühl, C., Mølsted-Pedersen, L., Petersen, K., & Christensen, M. S. (1985) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(85)90460-0 · Cited by 67
Bahamondes, L., Monteiro-Dantas, C., Espejo-Arce, X., dos Santos Fernandes, A. M., Lui-Filho, J. F., Perrotti, M., & Petta, C. A. (2006) · Human Reproduction · doi:10.1093/humrep/dei358 · Cited by 66
BUSEN, N., BRITT, R., & RIANON, N. (2003) · Journal of Adolescent Health · doi:10.1016/s1054-139x(02)00567-0 · Cited by 66
Garg, S. K. (1994) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1994.03510380055037 · Cited by 63
Beksinska, M. E., Smit, J. A., Kleinschmidt, I., Milford, C., & Farley, T. M. M. (2010) · Contraception · doi:10.1016/j.contraception.2009.07.007 · Cited by 61
Kjos, S. L., Shoupe, D., Douyan, S., Friednman, R. L., Bernstein, G. S., Mestman, J. H., & Mishell, D. R. (1990) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(90)90757-x · Cited by 55
Drug interactions between hormonal contraceptives and psychotropic drugs: a systematic review
Berry-Bibee, E. N., Kim, M.-J., Simmons, K. B., Tepper, N. K., Riley, H. E. M., Pagano, H. P., & Curtis, K. M. (2016) · Contraception · doi:10.1016/j.contraception.2016.07.011 · Cited by 52
Self-citationVestergaard, P., Rejnmark, L., & Mosekilde, L. (2008) · Contraception · doi:10.1016/j.contraception.2008.07.014 · Cited by 51
Cited by
Writing Committee Members*, Jones, D. W., Ferdinand, K. C., Taler, S. J., Johnson, H. M., Shimbo, D., Abdalla, M., Altieri, M. M., Bansal, N., Bello, N. A., et al. (2025) · Hypertension · doi:10.1161/hyp.0000000000000249 · Cited by 310
Jones, D. W., Ferdinand, K. C., Taler, S. J., Johnson, H. M., Shimbo, D., Abdalla, M., Altieri, M. M., Bansal, N., Bello, N. A., Bress, A. P., et al. (2025) · JACC · doi:10.1016/j.jacc.2025.05.007 · Cited by 280
Writing Committee Members*, Jones, D. W., Ferdinand, K. C., Taler, S. J., Johnson, H. M., Shimbo, D., Abdalla, M., Altieri, M. M., Bansal, N., Bello, N. A., et al. (2025) · Circulation · doi:10.1161/cir.0000000000001356 · Cited by 213
Misoprostol for intrauterine device placement
Zapata, L. B., Snyder, E., Nguyen, A. T., Kapp, N., Ti, A., Whiteman, M. K., & Curtis, K. M. (2025) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015584.pub2 · Cited by 3
Self-citation
Metadata
- Authors
- Nguyen, A. T., Curtis, K. M., Tepper, N. K., Kortsmit, K., Brittain, A. W., Snyder, E. M., Cohen, M. A., Zapata, L. B., Whiteman, M. K., Contributors, Baker, C., Dethier, D., Garbarino, S., Gold, H., Halper, E., Kapp, N., Krishna, G., Meurice, M., Ramer, S., Rodenhizer, J., Verma, N., & Wright, S.
- Venue
- MMWR. Recommendations and Reports
- Published
- 2024-08-08
- Volume
- 73
- Issue
- 4
- Pages
- 1-126
- ISSN
- 1057-5987 (ISSN-L)
- 1545-8601
- OpenAlex
- W4401358853
- Cited by
- 241
- References
- 41
- FWCI
- 89.33
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.